U.S. pharma large copyright scrapped two experimental weight loss pills very last year—a at the time-every day tablet, lotiglipron, as a consequence of elevated liver enzymes and also a twice-day by day pill, danuglipron, as a consequence of strong side effects—but CEO Albert Bourla has claimed the company is determined to “Participate in and